Format
Sort by

Send to:

Choose Destination

Results: 4

1.

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.

Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP; Motavizumab Cardiac Study Group.

Pediatr Res. 2011 Aug;70(2):186-91. doi: 10.1038/pr.2011.411.

PMID:
21522037
[PubMed - indexed for MEDLINE]
2.

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group.

Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.

PMID:
20008423
[PubMed - indexed for MEDLINE]
Free Article
3.

[The significance of cardiac symptoms in patients referred to pediatric cardiology outpatient clinics].

Kawalec W, Zuk M, Białkowski J, Pikulska-Orłowska H, Rudziński A, Siwińska A, Sysa A, Szydłowski L, Werner B, Czarnecki J, Ereciński J, Maćkowska K, Olszanowski A.

Med Wieku Rozwoj. 2005 Apr-Jun;9(2):139-51. Polish.

PMID:
16085955
[PubMed - indexed for MEDLINE]
4.

[Kawasaki disease--personal observations].

Dylewska K, Maćkowska K, Masłowska E, Kojro-Wojcieszonek A, Balcar-Boroń A.

Wiad Lek. 2001;54(3-4):215-8. Polish.

PMID:
11436689
[PubMed - indexed for MEDLINE]
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk